Abstract
128 12 hrs urine collections were made in patients presenting with central PP receiving the GnRH agonist B, either subcutaneously (SC) (13 girls and 5 boys) or intranasally (IN) (7 girls and 4 boys). Centers from Belgium, France, Germany, Holland and Switzerland participated in this study. Urinary excretion of immunoreactive B and B metabolites measured after SC administration of 20μg/kg once a day in 14 girls with good control was 88.5 ± 7.5μg (mean ± SEM) during the first 12hrs and 6.0±1.2μg during the following 12hrs. Mean E2 levels under therapy was 8.9±0.9pg/ml. 6 girls receiving 20μg/kg t.i.d. has an excretion of 91.5±8.7 and 89.5±9.2μg/12hrs, respectively. Two girls with poor control showed excretion levels similar to those with good control. In the 5 boys treated SC, similar levels to those measured in girls were found. One of them remained resistant (T>3.8ng/ml). In the 5 girls and 4 boys receiving IN 28.7±1.5μg/day of B, urinary excretion was 4.3±0.9μg/12hrs during daytime and 2.9±0.8μg during nighttime. Clinical control was poor in 2 girls: both had excretion values of 0.004 and 0.093μg, and 0.001 and 0.081μg/12hrs, suggesting a poor compliance or a non-absorption by the nasal mucosa. In a third one with Albright's syndrome, resistance to therapy was observed with B excretion of 1.4 and 1.1μg/12hrs. Measurement of B excretion is of value for the evaluation of control of the therapy, compliance or resistance, particularly when B is administered IN.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sizonenko, P., Reznik, Y. & Aubert, M. URINARY EXCRETION OF BUSERELIN (B) DURING THERAPY OF CENTRAL PRECOCIOUS PUBERTY (PP). A MULTICENTER STUDY. Pediatr Res 20, 1198 (1986). https://doi.org/10.1203/00006450-198611000-00147
Issue Date:
DOI: https://doi.org/10.1203/00006450-198611000-00147